Study Title: A Phase 2, Multicenter, Open label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First Line Treatment (CodeBreaK 201)
For more information about the trial above please contact the study team: